ArticleCancers2023
Melanoma Mortality Trends in 28 European Countries: A Retrospective Analysis for the Years 1960-2020.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.Dermatology and therapy · 2026Article
- Temporal Trends of Melanoma and Non-Melanoma Skin Cancer Mortality Rates in Hungary Between 1980 and 2020.Cancers · 2026Article
- Trends in Incidence and Mortality of Primary Cutaneous Melanoma in Serbia Between 2008 and 2022.Medicina (Kaunas, Lithuania) · 2026Article
- Long-term changes in melanoma epidemiology in Hungary: who are the high-risk groups, and where should we concentrate prevention programs?BMC public health · 2026Article
- Trends in Survival and Cure Indicators of Thin and Thick Cutaneous Malignant Melanoma in Italy.Cancer medicine · 2026Article
- Incidence and mortality of nonmelanoma skin cancer in Europe: current trends and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Exploring the Link Between PACAP Signalling and Hyaluronic Acid Production in Melanoma Progression.International journal of molecular sciences · 2025Article
- A highly accurate risk factor-based XGBoost multiethnic model for identifying patients with skin cancer.Nature communications · 2025Article
- Comprehensive Genomic Profiles of Melanoma in Veterans Compared to Reference Databases.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025Article
- Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data.Cancers · 2025Review
- Patterns and trends in melanoma mortality in Spain (1999-2022).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Overview of skin cancer types and prevalence rates across continents.Cancer pathogenesis and therapy · 2025Review
- Training Family Medicine Residents in Dermoscopy Using an e-Learning Course: Pilot Interventional Study.JMIR formative research · 2024Article
- Trends in Melanoma Mortality in Serbia: A 22-Year Population-Based Study.Iranian journal of public health · 2024Article
- Current knowledge about immunotherapy resistance for melanoma and potential predictive and prognostic biomarkers.Cancer drug resistance (Alhambra, Calif.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2020, in 27 European Union (EU) Member States, melanoma accounted for 4% of all new cancer cases and 1.3% of all cancer deaths, making melanoma the fifth most common malignancy and placing it in the 15 most frequent causes of cancer deaths in the EU-27. The main aim of our study was to investigate melanoma mortality trends in 25 EU Member States and three non-EU countries (Norway, Russia, and Switzerland) in a broad time perspective (1960-2020) in a younger (45-74 years old) vs. older age group (75+).
methodsWe identified melanoma deaths defined by ICD-10 codes C-43 for individuals aged 45-74 and 75+ years old between 1960-2020 in 25 EU Member States (excluding Iceland, Luxembourg, and Malta) and in 3 non-EU countries-Norway, Russia, and Switzerland. Age-standardized melanoma mortality rates (ASR) were computed using the direct age-standardization for Segi's World Standard Population. To determine melanoma-mortality trends with 95% confidence intervals (CI), Joinpoint regression was applied. Our analysis used the Join-point Regression Program, version 4.3.1.0 (National Cancer Institute, Bethesda, MD, USA).
resultsRegardless of the considered age groups, in all investigated countries, in general, melanoma standardized mortality rates were higher for men than women. Considering the age group 45-74, the highest number of countries was characterized by decreasing melanoma-mortality trends in both sexes-14 countries. Contrarily, the highest representation of countries in the age group 75+ was connected with increasing melanoma-mortality trends in both sexes-26 countries. Moreover, considering the older age group-75+-there was no country with a decreasing melanoma mortality in both sexes.
conclusionsInvestigated melanoma-mortality trends vary in individual countries and age groups; however, a highly concerning phenomenon-increasing melanoma-mortality rates in both sexes-was observed in 7 countries for the younger age group and in as many as 26 countries for the older age group. There is a need for coordinated public-health actions to address this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.